Melanoma associated peptide analogues and vaccines against...

Details Melanoma associated peptide analogues and vaccines against... Melanoma associated peptide analogues and vaccines against...

2010-12-06

2011-12-13

Rawlings, Stephen (Department: 1643)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C530S328000, C514S015800

Reexamination Certificate

active

08075900

ABSTRACT:
The present invention is concerned with cancer treatment and diagnosis, especially with melanoma associated peptide analogues with improved immunogenicity, epitopes thereof; vaccines against melanoma, tumor infiltrating T lymphocytes recognizing the antigen and diagnostics for the detection of melanoma and for the monitoring of vaccination. The peptides according to the invention can be exploited to elicit native epitope-reactive Cm. Usage of the peptides with improved immunogenicity may contribute to the development of CTL-epitope based vaccines in viral disease and cancer.

REFERENCES:
patent: 4405712 (1983-09-01), Vande Woude et al.
patent: 4485086 (1984-11-01), Wong
patent: 4497796 (1985-02-01), Salser et al.
patent: 4727028 (1988-02-01), Santerre et al.
patent: 4740463 (1988-04-01), Weinberg et al.
patent: 5190931 (1993-03-01), Inouye
patent: 5208149 (1993-05-01), Inouye
patent: 5262177 (1993-11-01), Brown et al.
patent: 5342774 (1994-08-01), Boon et al.
patent: 5376531 (1994-12-01), Anderson et al.
patent: 5518913 (1996-05-01), Massie et al.
patent: 5639860 (1997-06-01), Tanaka et al.
patent: 5643873 (1997-07-01), Barrett et al.
patent: 5648458 (1997-07-01), Cwirla et al.
patent: 5728802 (1998-03-01), Barrett et al.
patent: 5731172 (1998-03-01), Saito et al.
patent: 5783567 (1998-07-01), Hedley et al.
patent: 5837511 (1998-11-01), Falck-Pedersen et al.
patent: 5844075 (1998-12-01), Kawakami et al.
patent: 5874560 (1999-02-01), Kawakami et al.
patent: 5891432 (1999-04-01), Hoo
patent: 5965381 (1999-10-01), van der Bruggen et al.
patent: 5965535 (1999-10-01), Chaux et al.
patent: 5994106 (1999-11-01), Kovesdi et al.
patent: 5994128 (1999-11-01), Fallaux et al.
patent: 5994523 (1999-11-01), Kawakami et al.
patent: 6033908 (2000-03-01), Bout et al.
patent: 6040174 (2000-03-01), Imler et al.
patent: 6194195 (2001-02-01), Tanaka et al.
patent: 6204052 (2001-03-01), Bout et al.
patent: 6245525 (2001-06-01), Martelange et al.
patent: 6270778 (2001-08-01), Kawakami et al.
patent: 6291430 (2001-09-01), Chaux et al.
patent: 6303756 (2001-10-01), Martelange et al.
patent: 6369211 (2002-04-01), Chaux et al.
patent: 6407063 (2002-06-01), Luiten et al.
patent: 6426217 (2002-07-01), Chaux et al.
patent: 6500919 (2002-12-01), Adema et al.
patent: 6537560 (2003-03-01), Kawakami et al.
patent: 7846450 (2010-12-01), Figdor et al.
patent: 2002/0076392 (2002-06-01), Hoo
patent: 2003/0096787 (2003-05-01), Perricaudet et al.
patent: 2003/0144482 (2003-07-01), Kawakami et al.
patent: 2004/0156861 (2004-08-01), Figdor et al.
patent: 2 053 187 (1993-04-01), None
patent: 0 174 608 (1986-03-01), None
patent: 0 668 350 (1995-08-01), None
patent: 2 707 664 (1995-01-01), None
patent: 9-27482 (1997-01-01), None
patent: WO 92/21767 (1992-12-01), None
patent: WO 93/14189 (1993-04-01), None
patent: WO 94/23067 (1994-10-01), None
patent: WO 94/28152 (1994-12-01), None
patent: WO 95/02697 (1995-01-01), None
patent: WO 95/22561 (1995-08-01), None
patent: WO 95/29193 (1995-11-01), None
patent: WO 98/02538 (1998-01-01), None
patent: WO 98/31398 (1998-07-01), None
patent: WO 99/06544 (1999-02-01), None
patent: WO 99/14326 (1999-03-01), None
patent: WO 99/45098 (1999-09-01), None
patent: WO 99/53061 (1999-10-01), None
patent: WO 00/20445 (2000-04-01), None
patent: WO 00/20581 (2000-04-01), None
Arceci, RJ., The potential for antitumor vaccination in acute myelogenous leukemia, Journal of Molecular Medicine, 1998, pp. 80-93, vol. 76.
Bakker et al., Int. J. Cancer, Jan. 27, 1997, pp. 302-309, vol. 70 (3).
Bodey et al., Failure of cancer vaccines: the significant limitations of this approach to immunotherapy, Anticancer Research, 2000, pp. 2665-2676, vol. 20.
Boon, T., Toward a genetic analysis of tumor rejection antigens, Advances in Cancer Research, 1992, pp. 177-210, vol. 58.
Burgess et al., Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic: Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue, J. Cell Bio1,1990, 11:2129-2138.
Cox et al., Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines, Science, 1994, pp. 716-719, vol. 264.
Curti, Crit. Rev. Oncol/Hematol. 14:29-39, 1993.
De Vries et al., Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions, Cancer Research, 1997, pp. 3223-3229, vol. 57, No. 15.
Ezzell, C., Cancer “vaccines”: an idea whose time has come?, Journal of NIH Research, pp. 46-49, vol. 7, 1995.
Gao et al., Tumor vaccination that enhances antitumor T-cell responses does not inhibit the growth of established tumor, Journal of Immunotherapy, 2000, pp. 643-653, vol. 23, No. 6.
Gura, T., Systems for identifying drugs are often faulty, Science, 1997, pp. 1041-1042, vol. 278.
Hu et al., Enhancement of cytolytic T lymphocyte precursor frequence in melanoma patients following immunization with MAGE-1 peptide, Cancer Research, 1996, pp. 2479-2483, vol. 56.
Jaeger et al, Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo, International Journal of Cancer, 1996, pp. 162-169, vol. 66, No. 2.
Kristensen et al., Evidence that the newly cloned low-density-lipoprotein receptor related protein (LRP) is the alpha 2-macroglobulin receptor, Febs Letters, Dec. 1990, pp. 151-155, vol. 256, No. 1,2.
Lee et al., Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation butdoes not leadto tumor regression, Journal of Immunology, 1999, pp. 6292-6300, vol. 163.
Mukherji et al., Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization, proceedings of the National Academy of Science, 1995, pp. 8078-8082, vol. 92.
Gillies et al., Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities, Human Antibody. Hybridomas, 1990, vol. 1, No. 1, pp. 47-54.
Jain, Sci. Am. 271:58-65, 1994.
Kwon et al., A melanocyte-specific gene. Pmel 17, maps near the silver coat color locus on mouse chromosome 10 and is in a syntenic region on human chromosome 12, Proceedings of the National Academy of Sciences of USA, 88(20)9228-9232, Oct. 15, 1991, Washington D.C., USA.
Lazar et al., Transforming Growth Factor a: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, Mol. Cell Biol., 1988, vol. 8, pp. 1247-1252.
Osband et al., Problems in the investigational study and clinical use of cancer immunotherapy, Immunology Today, 1990, 11(6):193-195.
Rivoltini et al., Binding and Presentation of Peptides Derived from Melanoma Antigens MART-1 and Glycoprotein-100 by HLA-A2 Subtypes, Journal of Immunology, May 1996, pp. 3882-3891.
Marchand et al., Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3, Int. J. Cancer, 1995 63, 883-885, Wiley-Liss, Inc.
Rosenberg et al., Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma, Nature Medicine, Mar. 1998, vol. 4, No. 3, pp. 321-327.
Rosenberg, Cancer vaccines based on the identification of genes encoding cancer regression antigens, Immunology Today, vol. 18, No. 4, Apr. 1997, pp. 175-182.
Salgaller et al., Immunization against Epitopes in the Human Melanoma Antigen gp100 following Patient Immunization with Synthetic Peptides, Cancer Research, Oct. 1996, pp. 4749-4757, vol. 56.
Sinkovics et al., Vaccination against human cancers (review), International Journal of Cancer, 2000, pp. 81-96, vol. 16.
Slingluff et al., Melanomas with concordant loss of multiple differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens, Cancer Immunology & Immunotherapy, 2000, pp. 661-672, vol. 48, No. 12.
Slingluff et al., Recognition of Human Melanoma Cells by HLA-A2.1-Restricted Cytotoxic T Lymphocytes Is Mediated by at Least Six Shared Peptide Epitopes, The Journal of Immu

Affiliated with

Also associated with

Rating

Melanoma associated peptide analogues and vaccines against... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Melanoma associated peptide analogues and vaccines against..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Melanoma associated peptide analogues and vaccines against... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4309753